In 2007, approximately 33 million people were living with HIV/AIDS worldwide, while an estimated 2.5 million new infections occurred and 2.1 million AIDS-related deaths. With >95% of new infections occurring in low and middle income countries with limited access to antiretroviral therapy, the development of a prophylactic HIV vaccine remains one of the worlds top public health priorities. Many studies illustrate the important role of CD8+ T lymphocytes, also known as cytotoxic T lymphocytes (CTL), in controlling HIV and simian immunodeficiency virus (SIV) replication. However, the correlates...